The CRO just took in Continuum Clinical’s Late Stage research practice and folded it into its Evidence business unit.
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.
Arbor Biotechnologies has emerged from the shadows with $15.6 million in funding and a CRISPR enzyme that targets RNA.
Two studies uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.
Ionis Pharma is licensing two antisense drugs to Akcea Therapeutics, picking up a $150 million upfront fee.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
Alexion hit key endpoints for its experimental phase 3 drug ALXN1210 in patients with a life-threatening ultrarare blood disorder.
Ideaya expects to get its first synthetic lethality and immuno-oncology assets into human testing in the first half of next year.
Median PFS is still ticking up in the trial of the CD19 antibody, adding weight to MorphoSys’ claims MOR208 can hold its own against CAR-T therapies.